Form 4: Boston Scientific Director Edward Ludwig Acquires Shares

Edward Ludwig, a Director at Boston Scientific Corp, reported the acquisition of 3,800 shares of common stock on May 7, 2026, as part of an annual equity award.

Summary

• Director Edward Ludwig acquired 3,800 shares of Boston Scientific Corp common stock on May 7, 2026.
• This acquisition was part of an annual equity award valued at $215,000, based on the closing stock price on the grant date.
• The shares are restricted and will vest in full upon the next annual meeting of stockholders.
• Following this transaction, Ludwig beneficially owns 21,779 shares of common stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard insider equity award and an increase in beneficial ownership by a director, but does not indicate significant new strategic developments or financial performance.

Positives

• Director Edward Ludwig has increased his direct beneficial ownership of Boston Scientific Corp common stock.
• The acquisition of shares through an annual equity award indicates a commitment to aligning management and director interests with shareholders.
• The award is structured to vest upon the next annual meeting, encouraging continued engagement and performance.

Risks

• The acquired shares are subject to vesting conditions, meaning they are not fully owned by the director until the next annual meeting.
• The value of the award is dependent on the closing price of Boston Scientific Corp common stock on the grant date, introducing market risk.

Future Outlook

The acquired shares are subject to vesting, which will occur in full upon the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that insider equity awards are a common practice in the medical technology sector to incentivize leadership and align their interests with long-term company performance and shareholder value.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as it aligns director interests with shareholder value, though the amount is relatively small in the context of the company's overall market capitalization.

Next Steps

• Vesting of restricted stock upon the next annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific Corp, BSX, Form 4, Insider Transaction, Director, Equity Award, Restricted Stock, Beneficial Ownership